6-week Safety and PD Study in Adults With NAFLD

NCT03256526 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG: Placebo
DRUG: PF-06835919 Low Dose
DRUG: PF-06835919 High Dose

Sponsor

Pfizer